<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NEBUPENT- pentamidine isethionate inhalant </strong><br>APP Pharmaceuticals, LLC<br></p></div>
<h1>NebuPent</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="b5ae523a-a463-4e10-b70a-b584e07a2066"></a><a name="section-1"></a><p></p>
<h1></h1>
<span class="Bold"><span class="Emphasis">For Oral Inhalation Only</span></span>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="f47a23d7-bcda-4385-baac-8fc99d57832a"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">NebuPent (pentamidine isethionate), an antifungal agent, is a nonpyrogenic lyophilized product. After reconstitution with Sterile Water for Injection, USP, NebuPent is administered by inhalation via the Respirgard<span class="Sup">®</span> II nebulizer [Marquest, Englewood, CO] (see <span class="Bold"><span class="Emphasis"><a href="#f2eb6e45-57ab-441a-a178-e1b21077c0c5">DOSAGE AND ADMINISTRATION</a></span></span>).</p>
<p>Pentamidine isethionate, 4,4’-[1,5-pentane-diylbis(oxy)]bis-benzenecarboximidamid, is a white crystalline powder soluble in water and glycerin and insoluble in ether, acetone, and chloroform.</p>
<p><img alt="nebupent_structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e2ad9d3c-b6c3-4f70-87e0-722a8ff94ccb&amp;name=nebupent-figure-1-nebupent_structure.jpg"></p>
<br><p><span class="Bold"><span class="Emphasis">C<span class="Sub">19</span>H<span class="Sub">24</span>N<span class="Sub">4</span>O<span class="Sub">2</span>•2C<span class="Sub">2</span>H<span class="Sub">6</span>O<span class="Sub">4</span>S                            592.68</span></span></p>
<p>Each vial contains 300 mg pentamidine isethionate.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="c493d0b0-7091-4556-857d-d144734625de"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="34090-1">
<a name="ca3a9355-d1f7-43fe-b5f9-0746b8a2edf5"></a><a name="section-3.1"></a><p></p>
<h2>Microbiology<br>
</h2>
<p class="First"><span class="Bold"><span class="Emphasis">Mechanism of Action</span></span></p>
<p>Studies suggest that the pentamidine isethionate interferes with microbial nuclear metabolism by inhibition of DNA, RNA, phospholipid and protein synthesis.  However, the mode of action is not fully understood.</p>
<p><span class="Bold"><span class="Emphasis">Activity in vitro and in vivo</span></span></p>
<p>Pentamidine isethionate, an aromatic diamidine, is known to have activity against <span class="Italics"><span class="Emphasis">Pneumocystis jiroveci.</span></span></p>
<p><span class="Bold"><span class="Emphasis">Pharmacokinetics</span></span></p>
<p>In 5 AIDS patients with suspected <span class="Italics"><span class="Emphasis">Pneumocystis jiroveci</span></span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (PJP), the mean concentrations of pentamidine determined 18 to 24 hours after inhalation therapy were 23.2 ng/mL (range 5.1 to 43.0 ng/mL) in bronchoalveolar lavage fluid and 705 ng/mL (range 140 to 1336 ng/mL) in sediment after administration of a 300 mg single dose via the Respirgard<span class="Sup">®</span> II nebulizer. In 3 AIDS patients with suspected PJP, the mean concentrations of pentamidine determined 18 to 24 hours after a 4 mg/kg intravenous dose were 2.6 ng/mL (range 1.5 to 4.0 ng/mL) in bronchoalveolar lavage fluid and 9.3 ng/mL (range 6.9 to 12.8 ng/mL) in sediment. In the patients who received aerosolized pentamidine, the peak plasma levels of pentamidine were at or below the lower limit of detection of the assay (2.3 ng/mL).</p>
<p>Following a single 2-hour intravenous infusion of 4 mg/kg of pentamidine isethionate to 6 AIDS patients, the mean plasma Cmax, T 1/2 and clearance were 612 ± 371 ng/mL, 6.4 ± 1.3 hr and 248 ± 91 L/hr respectively. In another study of aerosolized pentamidine in 13 AIDS patients with acute PJP who received 4 mg/kg/day administered via the Ultra Vent<span class="Sup">®</span> jet nebulizer, peak plasma levels of pentamidine averaged 18.8 ± 11.9 ng/mL after the first dose. During the next 14 days of repeated dosing, the highest observed Cmax averaged 20.5 ± 21.2 ng/mL. In a third study, following daily administration of 600 mg of inhaled pentamidine isethionate with the Respirgard<span class="Sup">®</span> II nebulizer for 21 days in 11 patients with acute PJP, mean plasma levels measured shortly after the 21st dose averaged 11.8 ± 10.0 ng/mL. Plasma concentrations after aerosol administration are substantially lower than those observed after a comparable intravenous dose. The extent of pentamidine accumulation and distribution following chronic inhalation therapy are not known.</p>
<p>In rats, intravenous administration of a 5 mg/kg dose resulted in concentrations of pentamidine in the liver and kidney that were 87.5 and 62.3-fold higher, respectively, than levels in those organs following 5 mg/kg administered as an aerosol.</p>
<p>No pharmacokinetic data are available following aerosol administration of pentamidine in humans with impaired hepatic or renal function.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="f82f4fce-f867-4ad9-9925-0cc68b6e579d"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">NebuPent is indicated for the prevention of <span class="Italics"><span class="Emphasis">Pneumocystis jiroveci</span></span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (PJP) in high-risk, HIV-infected patients defined by one or both of the following criteria:</p>
<p>i. a history of one or more episodes of PJP</p>
<p>ii. a peripheral CD4+ (T4 helper/inducer) lymphocyte count less than or equal to 200/mm<span class="Sup">3</span>.</p>
<p>These indications are based on the results of an 18-month randomized, dose-response trial in high risk HIV-infected patients and on existing epidemiological data from natural history studies.</p>
<p>The patient population of the controlled trial consisted of 408 patients, 237 of whom had a history of one or more episodes of PJP. The remaining patients without a history of PJP included 55 patients with Kaposi’s <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcoma</span> and 116 patients with other AIDS diagnoses, ARC or <span class="product-label-link" type="condition" conceptid="4241530" conceptname="Asymptomatic human immunodeficiency virus infection">asymptomatic HIV infection</span>. Patients were randomly assigned to receive NebuPent via the Respirgard<span class="Sup">®</span> II nebulizer at one of the following three doses: 30 mg every two weeks (n=135), 150 mg every two weeks (n=134) or 300 mg every four weeks (n=139). The results of the trial demonstrated a significant protective effect (p&lt;0.01) against PJP with the 300 mg every four week dosage regimen compared to the 30 mg every two week dosage regimen. The 300 mg dose regimen reduced the risk of developing PJP by 50 to 70% compared to the 30 mg regimen. A total of 293 patients (72% of all patients) also received zidovudine at sometime during the trial. The analysis of the data demonstrated the efficacy of the 300 mg dose even after adjusting for the effect of zidovudine.</p>
<p>The results of the trial further demonstrate that the dose and frequency of dosing are important to the efficacy of NebuPent prophylaxis in that multiple analyses consistently demonstrated a trend toward greater efficacy with 300 mg every four weeks as compared to 150 mg every two weeks.</p>
<p>No dose-response was observed for reduction in overall mortality; however, mortality from PJP was low in all three dosage groups. </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="a9361ec1-9b91-46e0-b632-16fd0b2f960d"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">NebuPent is contraindicated in patients with a ­history of an <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span> to inhaled or parenteral pentamidine isethionate.<br></p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="ce874c18-3d71-48af-a93f-deda0a86b335"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">The potential for development of acute PJP still exists in patients receiving NebuPent prophylaxis. Therefore, any patient with symptoms suggestive of the presence of a pulmonary <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, including but not limited to <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, should receive a thorough medical evaluation and appropriate diagnostic tests for possible acute PJP as well as for other opportunistic and nonopportunistic pathogens. The use of NebuPent may alter the clinical and radiographic features of PJP and could result in an atypical presentation, including but not limited to mild disease or focal ­<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p>Prior to initiating NebuPent prophylaxis, symptomatic patients should be evaluated appropriately to exclude the presence of PJP. The recommended dose of NebuPent for the prevention of PJP is insufficient to treat acute PJP.<br></p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="e2dc8446-1f71-4afc-9faa-b73055017754"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First"><span class="Bold"><span class="Emphasis">IMPORTANT: DO NOT MIX THE NEBUPENT SOLUTION WITH ANY OTHER DRUGS. DO NOT USE THE RESPIRGARD</span></span><span class="Sup">®</span><span class="Bold"><span class="Emphasis"> II NEBULIZER TO ADMINISTER A BRONCHODILATOR.</span></span> (See <span class="Bold"><span class="Emphasis"><a href="#f2eb6e45-57ab-441a-a178-e1b21077c0c5">DOSAGE AND ADMINISTRATION</a></span></span>).</p>
<br><div class="Section" data-sectionCode="42232-9">
<a name="a208f861-03fd-48d7-87e6-a460b346e517"></a><a name="section-7.1"></a><p></p>
<h2>Pulmonary<br>
</h2>
<p class="First">Inhalation of NebuPent may induce <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> or <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>. This has been noted particularly in some patients who have a history of smoking or <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. In clinical trials, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> and <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> were the most frequently reported adverse experiences associated with NebuPent administration (38% and 15%, respectively of patients receiving the 300 mg dose); however less than 1% of the doses were interrupted or terminated due to these effects. For the majority of patients, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> and <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> were controlled by administration of an aerosolized bronchodilator (only 1% of patients withdrew from the study due to treatment-associated <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> or <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>). In patients who experience <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> or <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, administration of an inhaled bronchodilator prior to giving each NebuPent dose may minimize recurrence of the symptoms.<br></p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="d277861d-f4cb-4607-90b8-cde6c94be8ef"></a><a name="section-7.2"></a><p></p>
<h2>General<br>
</h2>
<p class="First">The extent and consequence of pentamidine accumulation following chronic inhalation therapy are not known. As a result, patients receiving NebuPent should be closely monitored for the development of serious adverse reactions that have occurred in patients receiving parenteral pentamidine, including <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, hypogly­cemia, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, hepatic or renal dysfunction, <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>, pancre­atitis, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> and abnormal ST segment of ECG.</p>
<p>Extrapulmonary <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with <span class="Italics"><span class="Emphasis">P. jiroveci</span></span> has been reported infrequently. Most, but not all, of the cases have been reported in patients who have a history of PJP. The presence of extrapulmonary <span class="product-label-link" type="condition" conceptid="438350" conceptname="Pneumocystosis">pneumocystosis</span> should be considered when evaluating patients with unexplained signs and symptoms.</p>
<p>Cases of <span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">acute pancreatitis</span> have been reported in patients receiving aerosolized pentamidine. NebuPent should be discontinued if signs or symptoms of <span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">acute pancreatitis</span> develop.<br></p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="d7590e13-601e-412d-a2ff-7c57c53afa02"></a><a name="section-7.3"></a><p></p>
<h2>Drug Interactions<br>
</h2>
<p class="First">While specific studies on drug interactions with NebuPent have not been conducted, the majority of patients in clinical trials received concomitant medications, including zidovudine, with no reported interactions. Because the nephrotoxic effects may be additive, the concomitant or sequential use of NebuPent and other nephrotoxic drugs such as aminoglycosides, amphotericin B, cisplatin, foscarnet, or vancomycin should be closely monitored and avoided, if possible.<br></p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="d4eb7451-5d9b-417f-875d-8d351f31307a"></a><a name="section-7.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis and Impairment of Fertility<br>
</h2>
<p class="First">Literature reports indicate that pentamidine was not mutagenic in the Ames bacterial <span class="Italics"><span class="Emphasis">(S. typhimurium)</span></span> test and did not induce an increase in chromosomal aberrations in Chinese Hamster Ovary (CHO) cell or in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> <span class="Italics"><span class="Emphasis">in vitro</span></span>.</p>
<p>No studies have been conducted to determine effects of pentamidine isethionate on carcinogenicity or fertility.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="ae2a524a-94de-4f9a-8dfb-0ae45d32367c"></a><a name="section-7.5"></a><p></p>
<h2>Pregnancy-Pregnancy Category C<br>
</h2>
<p class="First">There are no adequate and well controlled studies of NebuPent in pregnant women.  A literature report indicated that intravenously administered pentamidine in pregnant rats at 4 mg/kg/day was embryolethal; <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> was not observed in this study.  It is unknown whether pentamidine administered via the aerosolized route crosses the placenta at clinically significant concentrations.  It is not known whether NebuPent can cause fetal harm when administered to a pregnant woman.  NebuPent should be given to a pregnant woman only if clearly needed.<br></p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="a9241033-0738-417f-9ee8-0d07c53f4a6e"></a><a name="section-7.6"></a><p></p>
<h2>Nursing Mothers<br>
</h2>
<p class="First">It is not known whether NebuPent is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from NebuPent, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Because many drugs are excreted in human milk, NebuPent should not be given to a nursing mother unless the potential benefits are judged to outweigh the unknown risks.<br></p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="d24bacfb-a2b4-419f-90f9-32dfc493e71a"></a><a name="section-7.7"></a><p></p>
<h2>Pediatric Use<br>
</h2>
<p class="First">The safety and effectiveness of NebuPent in pediatric patients (birth to 16 years of age) have not been established.<br></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="cf9f05fe-1bed-4945-b97f-e5e660552457"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The most frequently reported unsolicited adverse events (1 to 5%) in clinical trials, regardless of their relation to NebuPent therapy were as follows (n=931):</p>
<p> <span class="Italics"><span class="Emphasis">Body as a Whole:</span></span> <span class="product-label-link" type="condition" conceptid="4181178" conceptname="Night sweats">Night sweats</span>.</p>
<p> <span class="Italics"><span class="Emphasis">Gastrointestinal:</span></span> <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>.</p>
<p> <span class="Italics"><span class="Emphasis">Hematologic:</span></span> <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>.</p>
<p> <span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>:</span></span> <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span>, non-specific herpes, ­<span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>, non-specific <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>, <span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">oral Candida</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, and upper ­respiratory tract.</p>
<p> <span class="Italics"><span class="Emphasis">Nervous System:</span></span> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>.</p>
<p> <span class="Italics"><span class="Emphasis">Respiratory System:</span></span> <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, and <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>.</p>
<p> <span class="Italics"><span class="Emphasis">Special Senses:</span></span> Bad taste.</p>
<p>Adverse events of less than 1% incidence were as follows (No causal relationship to treatment has been established for these adverse events):</p>
<p> <span class="Italics"><span class="Emphasis">Body as a Whole:</span></span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reaction</span>, non-specific <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span>, <span class="product-label-link" type="condition" conceptid="4178504" conceptname="Body odor">body odor</span>, facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">leg edema</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, low body temperature, and temperature abnormality.</p>
<p> <span class="Italics"><span class="Emphasis">Cardiovascular:</span></span> <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Cerebrovascular accident</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, poor circulation, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span> and <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>.</p>
<p> <span class="Italics"><span class="Emphasis">Gastrointestinal:</span></span> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcer</span>, <span class="product-label-link" type="condition" conceptid="4281516" conceptname="Gingivitis">gingivitis</span>, <span class="product-label-link" type="condition" conceptid="4224004" conceptname="Hiatal hernia">hiatal hernia</span>, <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">hypersalivation</span>, oral <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span>/<span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span>, <span class="product-label-link" type="condition" conceptid="200527" conceptname="Splenomegaly">splenomegaly</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p> <span class="Italics"><span class="Emphasis">Hematological:</span></span> <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, non-specific <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">cytopenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
<p> <span class="Italics"><span class="Emphasis">Hepatic:</span></span> <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span>, <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>, and hepatic dysfunction.</p>
<p> <span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>:</span></span> Bacterial <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, central venous line related <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="432310" conceptname="Cryptococcal meningitis">cryptococcal meningitis</span>, cytomegalovirus (CMV) <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span>, <span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">esophageal Candida</span>, <span class="product-label-link" type="condition" conceptid="433134" conceptname="Histoplasmosis">histoplasmosis</span>, Kaposi’s <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcoma</span>, non-specific mycoplasma, <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">oral herpes</span>, non-specific <span class="product-label-link" type="condition" conceptid="4183452" conceptname="Otitis">otitis</span>, non-specific <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, pharyngeal herpes, non-specific serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">tonsillitis</span>, <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>, and <span class="product-label-link" type="condition" conceptid="372547" conceptname="Viral encephalitis">viral encephalitis</span>.</p>
<p> <span class="Italics"><span class="Emphasis">Metabolic:</span></span> <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, and <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>.</p>
<p> <span class="Italics"><span class="Emphasis">Musculoskeletal:</span></span> <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>, <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>, and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>.</p>
<p> <span class="Italics"><span class="Emphasis">Neurological:</span></span> <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypesthesia</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">memory loss</span>, <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, non-specific <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="432590" conceptname="Delusional disorder">paranoia</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">unsteady gait</span>, and <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>.</p>
<p> <span class="Italics"><span class="Emphasis">Reproductive:</span></span> <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">Miscarriage</span>.</p>
<p> <span class="Italics"><span class="Emphasis">Respiratory system:</span></span> <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, chest congestion, <span class="product-label-link" type="condition" conceptid="4034235" conceptname="Tight chest">chest tightness</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">coryza</span>, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>, eosinophilic or <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial pneumonitis</span>, <span class="product-label-link" type="condition" conceptid="4091505" conceptname="Gagging">gagging</span>, <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span>, <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span>, <span class="product-label-link" type="condition" conceptid="24969" conceptname="Laryngitis">laryngitis</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span>, non-specific <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disorder</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="78786" conceptname="Pleurisy">pleuritis</span>, <span class="product-label-link" type="condition" conceptid="253796" conceptname="Pneumothorax">pneumothorax</span>, <span class="product-label-link" type="condition" conceptid="4167669" conceptname="Respiratory crackles">rales</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, non-specific <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span>, and <span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span>.</p>
<p> <span class="Italics"><span class="Emphasis">Skin:</span></span> <span class="product-label-link" type="condition" conceptid="135029" conceptname="Peeling of skin">Desquamation</span>, dry and breaking hair, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, non-specific <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
<p> <span class="Italics"><span class="Emphasis">Special senses:</span></span> <span class="product-label-link" type="condition" conceptid="378425" conceptname="Blepharitis">Blepharitis</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, contact lens <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span> or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, <span class="product-label-link" type="condition" conceptid="4300870" conceptname="Hemianopia">hemianopsia</span>, <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">loss of taste</span>, non-specific odor, and smell.</p>
<p> <span class="Italics"><span class="Emphasis">Urogenital:</span></span> <span class="product-label-link" type="condition" conceptid="4090433" conceptname="Flank pain">Flank pain</span>, <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">incontinence</span>, <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, and <span class="product-label-link" type="condition" conceptid="4167250" conceptname="Renal pain">renal pain</span>.</p>
<p>In a clinical trial where some adverse events were solicited by investigators, the incidences were as follows:</p>
<p><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span> (62.7%)</p>
<p><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased appetite</span> (50.0%)</p>
<p><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> or light-headedness (45.1%)</p>
<p><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span> (65.7%)</p>
<p><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> (51.0%)</p>
<p>Non-specific serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (15.2%)</p>
<p><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Shortness of breath</span> (48.3%)</p>
<p><span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">Wheezing</span> (32.4%)</p>
<p>From post-marketing clinical experience with NebuPent the following spontaneous adverse events have been reported: <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, esophigitis, <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">hematochezia</span>, increased blood urea nitrogen (BUN) and serum creatinine levels, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> (see <span class="Bold"><span class="Emphasis"><a href="#ce874c18-3d71-48af-a93f-deda0a86b335">WARNINGS</a></span></span>), syndrome of inappropriate antidiuretic hormone (<span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">SIADH</span>), and <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span>. </p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="bae64636-e349-4695-aab7-ebc8bb596663"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Overdosage has not been reported with NebuPent. The symptoms and signs of overdosage are not known.</p>
<p>A serious overdosage, to the point of producing systemic drug levels similar to those following parenteral administration, would have the potential of producing similar types of serious systemic toxicity. (See <span class="Bold"><span class="Emphasis"><a href="#e2dc8446-1f71-4afc-9faa-b73055017754">PRECAUTIONS</a></span></span>).</p>
<p>Available clinical pharmacology data (see <span class="Bold"><span class="Emphasis"><a href="#c493d0b0-7091-4556-857d-d144734625de">CLINICAL PHARMACOLOGY</a></span></span>) suggest that a dose up to 40 times the recommended NebuPent dosage would be required to produce systemic levels similar to a single 4 mg/kg intravenous dose.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="f2eb6e45-57ab-441a-a178-e1b21077c0c5"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold"><span class="Emphasis">IMPORTANT: NEBUPENT MUST BE DISSOLVED ONLY IN STERILE WATER FOR INJECTION, USP. DO NOT USE SALINE SOLUTION FOR RECONSTITUTION BECAUSE THE DRUG WILL PRECIPITATE. DO NOT MIX THE NEBUPENT SOLUTION WITH ANY OTHER DRUGS. DO NOT USE THE RESPIRGARD</span></span><span class="Sup">®</span><span class="Bold"><span class="Emphasis"> II NEBULIZER TO ADMINISTER A BRONCHODILATOR.</span></span></p>
<div class="Section" data-sectionCode="34068-7">
<a name="ec602101-8c4f-4b41-9638-ade74b66b6e2"></a><a name="section-10.1"></a><p></p>
<h2>Reconstitution<br>
</h2>
<p class="First">The contents of one vial (300 mg) must be dissolved in 6 mL Sterile Water for Injection, USP. Place the entire reconstituted contents of the vial into the Respirgard<span class="Sup">®</span> II nebulizer reservoir for administration.<br></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="c4e50bbc-6e0f-4186-aef3-78b24d3d299f"></a><a name="section-10.2"></a><p></p>
<h2>Dosage<br>
</h2>
<p class="First">The recommended adult dosage of NebuPent for the prevention of <span class="Italics"><span class="Emphasis">Pneumocystis jiroveci </span></span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> is 300 mg once every four weeks administered via the Respirgard<span class="Sup">®</span> II nebulizer.</p>
<p>The dose should be delivered until the nebulizer chamber is empty (approximately 30 to 45 minutes). The flow rate should be 5 to 7 liters per minute from a 40 to 50 pounds per square inch (PSI) air or oxygen source. Alternatively, a 40 to 50 PSI air compressor can be used with flow limited by setting the flowmeter at 5 to 7 liters per minute or by setting the pressure at 22 to 25 PSI. Low pressure (less than 20 PSI) compressors should not be used.<br></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="dc1e1d95-a4a0-442f-9ede-af69e8d843ab"></a><a name="section-10.3"></a><p></p>
<h2>Stability<br>
</h2>
<p class="First">Freshly prepared solutions for aerosol use are ­recommended. After reconstitution with sterile water, the NebuPent solution is stable for 48 hours in the original vial at room temperature if protected from light.<br></p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="dc0d426e-e3b9-4f14-b011-82acf69b95c1"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<table>
<colgroup>
<col align="left">
<col align="left">
<col align="left">
</colgroup>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<p class="First"><span class="Bold"><span class="Emphasis">Product </span></span></p>
<p><span class="Bold"><span class="Emphasis">No.</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<p class="First"><span class="Bold"><span class="Emphasis">NDC </span></span></p>
<p><span class="Bold"><span class="Emphasis">No.</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First"><span class="Bold"><span class="Emphasis"> </span></span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">87715</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">63323-877-15</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">NebuPent<span class="Sup">®</span> (pentamidine isethionate) 300 mg lyophilized product in single dose vials, individually packaged.</p></td>
</tr>
</tbody>
</table>
<p class="First">Store dry product at 20°to 25°C (68°to 77°F) [see USP Controlled Room Temperature].</p>
<p>Protect the dry product and the reconstituted solution from light.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="c9c1a8b1-00e9-401c-a85f-21bf8c747c25"></a><a name="section-12"></a><p></p>
<h1></h1>
<p class="First"><img alt="add_band_logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e2ad9d3c-b6c3-4f70-87e0-722a8ff94ccb&amp;name=nebupent-figure-2-add_band_logo.jpg"> </p>
<br><p>45847D</p>
<p>Revised: December 2010</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="fb0d4875-3b84-45a2-95d8-6b75addb2852"></a><a name="section-13"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold"><span class="Emphasis"> PACKAGE LABEL – PRINCIPAL DISPLAY – NebuPent  300 mg Single Dose Vial Label </span></span></p>
<p><span class="Bold"><span class="Emphasis"><span class="Bold"><span class="Emphasis"> NDC  </span></span></span></span>63323-877-15</p>
<p>87715</p>
<p><span class="Bold"><span class="Emphasis">NebuPent</span></span></p>
<p><span class="Bold Italics"><span class="Emphasis">(pentamidine isethionate)</span></span></p>
<p><span class="Bold"><span class="Emphasis">300 mg</span></span></p>
<p>Lyophilized</p>
<p>For Inhalation Solution</p>
<p>Single-Dose Vial</p>
<p>Rx only</p>
<p><img alt="nebupent_vlbl" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e2ad9d3c-b6c3-4f70-87e0-722a8ff94ccb&amp;name=nebupent-figure-3-nebupent_vlbl.jpg"></p>
<p><span class="Bold"><span class="Emphasis"><span class="Bold"><span class="Emphasis"><br></span></span></span></span></p>
<p><span class="Bold"><span class="Emphasis"> PACKAGE LABEL – PRINCIPAL DISPLAY – NebuPent  300 mg Single Dose Vial Carton Panel<br></span></span></p>
<p><span class="Bold"><span class="Emphasis">NebuPent</span></span></p>
<p><span class="Bold Italics"><span class="Emphasis">(pentamidine isethionate)</span></span></p>
<p><span class="Bold"><span class="Emphasis"><span class="Bold"><span class="Emphasis">NDC </span></span></span></span>63323-877-15</p>
<p>87715</p>
<p><span class="Bold"><span class="Emphasis">300 mg</span></span></p>
<p>Lyophilized</p>
<p>For Inhalation Solution</p>
<p>Single-Dose Vial</p>
<p>Rx only</p>
<p><img alt="nebupent_carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e2ad9d3c-b6c3-4f70-87e0-722a8ff94ccb&amp;name=nebupent-figure-4-nebupent_carton.jpg"> </p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NEBUPENT 		
					</strong><br><span class="contentTableReg">pentamidine isethionate inhalant</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63323-877</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">RESPIRATORY (INHALATION)</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PENTAMIDINE ISETHIONATE</strong> (PENTAMIDINE) </td>
<td class="formItem">PENTAMIDINE</td>
<td class="formItem">300 mg  in 6 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63323-877-15</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">6 mL in 1 VIAL, SINGLE-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019887</td>
<td class="formItem">02/15/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>APP Pharmaceuticals, LLC
							(608775388)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">APP Pharmaceuticals, LLC</td>
<td class="formItem"></td>
<td class="formItem">023648251</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>a74cc23c-ad4e-4a11-b060-1a533f726cd2</div>
<div>Set id: e2ad9d3c-b6c3-4f70-87e0-722a8ff94ccb</div>
<div>Version: 1</div>
<div>Effective Time: 20101207</div>
</div>
</div> <div class="DistributorName">APP Pharmaceuticals, LLC</div></p>
</body></html>
